Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

被引:11
|
作者
Kon, Hadas [1 ]
Hameir, Amichay [1 ]
Nutman, Amir [1 ,2 ]
Temkin, Elizabeth [1 ]
Keren Paz, Alona [1 ]
Lellouche, Jonathan [1 ,3 ]
Schwartz, David [1 ]
Weiss, David S. [4 ]
Kaye, Keith S. [5 ]
Daikos, George L. [6 ,7 ]
Skiada, Anna [6 ,7 ]
Durante-Mangoni, Emanuele [8 ,9 ]
Dishon Benattar, Yael [10 ,11 ]
Yahav, Dafna [2 ,12 ]
Daitch, Vered [2 ,13 ]
Bernardo, Mariano [14 ]
Iossa, Domenico [8 ]
Friberg, Lena E. [15 ]
Theuretzbacher, Ursula [16 ]
Leibovici, Leonard [2 ,13 ]
Dickstein, Yaakov [10 ]
Pollak, Dina [17 ]
Mendelsohn, Sigal [17 ]
Paul, Mical [10 ]
Carmeli, Yehuda [1 ,2 ]
AIDA Study Grp
机构
[1] Israel Minist Hlth, Natl Inst Antibiot Resistance & Infect Control, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] Ariel Univ, Adelson Sch Med, Ariel, Israel
[4] Emory Univ, Emory Antibiot Resistance Ctr, Sch Med, Atlanta, GA USA
[5] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[6] Laikon Gen Hosp, Dept Med 1, Athens, Greece
[7] Natl & Kapodistrian Univ Athens, Athens, Greece
[8] Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy
[9] AORN Colli Monaldi Hosp, Naples, Italy
[10] Inst Infect Dis, Rambam Hlth Care Campus, Haifa, Israel
[11] Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Techn, Haifa, Israel
[12] Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel
[13] Beilinson Med Ctr, Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel
[14] AORN Ospedali Colli Monaldi Hosp, Microbiol & Virol Unit, Naples, Italy
[15] Uppsala Univ, Dept Pharm, Uppsala, Sweden
[16] Ctr Antiinfect Agents, Vienna, Austria
[17] Microbiol Lab, Rambam Hlth Care Campus, Haifa, Israel
关键词
Acinetobacter baumannii; carbapenem-resistance; colistin; heteroresistance; population analysis profiling; ASSOCIATION; BLOOD;
D O I
10.1128/spectrum.05093-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Colistin heteroresistance (HR) refers to a bacterial population comprised of several subpopulations with different levels of resistance to colistin. In this study, we discuss the classic form of HR, in which a resistant subpopulation exists within a predominantly susceptible population. We investigated the prevalence of colistin HR and its evolution into full resistance among 173 clinical carbapenem-resistant Acinetobacter baumannii isolates and examined the effect of HR on clinical outcomes. To determine HR, we performed population analysis profiling. Our results showed a high prevalence of HR (67.1%). To examine evolution of HR strains into full resistance, the HR strains were grown in colistin-containing broth, transferred onto colistin-containing plates, and colonies on these plates were transferred into colistin-free broth. Many of the HR strains (80.2%) evolved into full resistance, 17.2% reverted to HR, and 2.6% were borderline. We used logistic regression to compare 14-day clinical failure and 14-day mortality between patients infected by HR versus susceptible non-HR carbapenem-resistant A. baumannii. In the subgroup of patients with bacteremia, HR was significantly associated with 14-day mortality.IMPORTANCE To our knowledge, this is the first large-scale study to report on HR in Gram-negative bacteria. We described the prevalence of colistin HR in a large sample of carbapenem-resistant A. baumannii isolates, the evolution of many colistin HR isolates to a resistant phenotype following colistin exposure and withdrawal, and the clinical consequences of colistin HR. We found a high prevalence of HR among clinical carbapenem-resistant A. baumannii isolates; most evolved into a resistant phenotype following colistin exposure and withdrawal. In patients treated with colistin, evolution of HR A. baumannii into full resistance could lead to higher rates of treatment failure and contribute to the reservoir of colistin-resistant pathogens in health care settings. To our knowledge, this is the first large-scale study to report on HR in Gram-negative bacteria. We described the prevalence of colistin HR in a large sample of carbapenem-resistant A. baumannii isolates, the evolution of many colistin HR isolates to a resistant phenotype following colistin exposure and withdrawal, and the clinical consequences of colistin HR.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] A global view on carbapenem-resistant Acinetobacter baumannii
    Mueller, Carina
    Reuter, Sandra
    Wille, Julia
    Xanthopoulou, Kyriaki
    Stefanik, Danuta
    Grundmann, Hajo
    Higgins, Paul G.
    Seifert, Harald
    MBIO, 2023, 14 (06)
  • [42] Treating carbapenem-resistant Acinetobacter baumannii infections
    Giannella, Maddalena
    Viale, Pierluigi
    LANCET INFECTIOUS DISEASES, 2023, 23 (09): : 994 - 995
  • [43] Colistin and Carbapenem-Resistant Acinetobacter baumannii Aci46 in Thailand: Genome Analysis and Antibiotic Resistance Profiling
    Thadtapong, Nalumon
    Chaturongakul, Soraya
    Soodvilai, Sunhapas
    Dubbs, Padungsri
    ANTIBIOTICS-BASEL, 2021, 10 (09):
  • [44] Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil
    Schimith, Karina Eugenia
    Luiz, Simone Oliveira
    Scheffer, Mara Cristina
    Gales, Ana Cristina
    Paganini, Maria Cristina
    do Nascimento, Agnaldo Jose
    Carignano, Evelyn
    Dalla Costa, Libera Maria
    AMERICAN JOURNAL OF INFECTION CONTROL, 2010, 38 (04) : 308 - 314
  • [45] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
    Apisarnthanarak, Anucha
    Jitpokasem, Sumana
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11): : 1235 - 1237
  • [46] Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms
    Skalweit, Marion J.
    Li, Mei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3013 - 3020
  • [47] INDICATIONS OF CARBAPENEM RESISTANCE EVOLUTION THROUGH HETERORESISTANCE AS AN INTERMEDIATE STAGE IN Acinetobacter baumannii AFTER CARBAPENEM ADMINISTRATION
    Superti, Silvana Vargas
    Martins, Daniela de Souza
    Caierao, Juliana
    Soares, Fabiana da Silva
    Prochnow, Taisa
    Zavascki, Alexandre Prehn
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2009, 51 (02): : 111 - 113
  • [48] Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients
    Katip, Wasan
    Uitrakul, Suriyon
    Oberdorfer, Peninnah
    PHARMACEUTICS, 2022, 14 (01)
  • [49] In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates
    Singkham-in, Uthaibhorn
    Chatsuwan, Tanittha
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 91 (02) : 169 - 174
  • [50] Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections
    Song, Joon Young
    Cheong, Hee Jin
    Choi, Won Suk
    Heo, Jung Yeon
    Noh, Ji Yun
    Kim, Woo Joo
    JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 60 (05) : 605 - 611